USPTO grants Charpentier-founded company first CRISPR patent

The US Patent and Trademark Office (USPTO) has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO grants another CRISPR patent to Charpentier

12 March 2019 The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.

Europe

EPO grants second CRISPR patent to ERS Genomics

7 March 2018 The European Patent Office has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.

Americas

PTAB says Broad's CRISPR patents do not interfere with UC Berkeley's

16 February 2017 The Broad Institute of Harvard and MIT’s patents concerning CRISPR technology do not interfere with patent claims filed by the University of California, Berkeley and the University of Vienna.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

USPTO grants Charpentier-founded company first CRISPR patent

More on this story

Editor's picks

Editor's picks

More features